🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 63 of 857 · Phase 3 first, then by program name

  1. Eplerenone

    Pfizer

    Heart Failure

    phase 3 small molecule completed

    1 trial

  2. Eplontersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  3. Eplontersen

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  4. Epoetin

    Takeda

    Chronic Kidney Disease

    phase 3 small molecule completed

    1 trial

  5. Epoetin alga (Epogen)/vadadustat

    Akebia Europe Limited

    Anemia Associated With Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  6. Eptinezumab

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule completed

    1 trial

  7. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  8. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  9. Erenumab

    United Therapeutics Europe Ltd

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  10. Erenumab, Placebo for AMG 334

    Amgen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  11. Eribulin Mesylate

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 3 small molecule on hold

    1 trial

  12. Eriobotyra Japonica Lindley Extract

    Hospital Authority, Hong Kong

    Cognitive Function

    phase 3 other completed

    1 trial

  13. Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  14. Ertapenem

    Iterum Therapeutics plc

    Intra Abdominal Infections

    phase 3 small molecule completed

    1 trial

  15. EryDex Low dose DSP

    Quince Therapeutics

    Nervous System Disease

    phase 3 small molecule completed

    1 trial

  16. EryDex System

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 other terminated

    1 trial

  17. Erythromycin

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  18. Erythropoiesis-Stimulating Agent (ESA)

    Akebia Europe Limited

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  19. Erythropoietin

    The First People's Hospital of Lianyungang

    Premature Infants

    phase 3 small molecule active

    1 trial

  20. EscharEx, Placebo (Gel Vehicle), Amnion/Chorion Membrane Allograft

    MediWound Germany GmbH

    Venous leg ulcer

    phase 3 small molecule active

    1 trial

  21. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial

  22. Escitalopram

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  23. Escitalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  24. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources